Gene therapy watch: 5 patients tracked for Long-Term safety after CS-101 treatment
NCT ID NCT06685536
First seen Mar 10, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study follows 5 people with beta-thalassemia who already received CS-101, a gene therapy that modifies their own blood stem cells. Researchers will monitor them for years to check for side effects and see if they remain free from needing blood transfusions. No new treatment is given in this follow-up study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Conditions
Explore the condition pages connected to this study.